Lupus
main-banner
Lupus
IM011-132 Enrolling

Research Trial for Cutaneous Lupus Erythematosus (60 Weeks)


Age: 18 Years

Adults aged 18 to 75 with a diagnosis of active discoid and/or subacute cutaneous lupus erythematosus (DLE/SCLE) for at least 3 months, may qualify to participate. Individuals must have active moderate to severe cutaneous lupus to be eligible for study entry. They must also currently be receiving treatment with a stable regimen of at least one of the following medications: an oral corticosteroid, and/or an antimalarial, and/or an immunosuppressant.

Participants will receive one of two dosages of investigational oral medication (active study drug) or placebo for 16 weeks. At Week 16, participants who previously received placebo will then receive one of two dosages of active study drug. Study medication and study-related procedures will be provided at no cost. Reimbursement for study-related expenses will also be provided.

Study participation will last about 60 weeks and involve about 12 visits to the study centre.


Official Title

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

ClinicalTrials.gov ID

NCT04857034

Sponsor

Bristol-Myers Squibb

Study Description

  • Brief Summary:

    Bristol-Myers Squibb

  • Condition or Disease:

    Lupus Erythematosus, Discoid,Lupus Erythematosus, Subacute Cutaneous

  • Intervention/Treatment:

    Drug: BMS-986165 Drug: BMS-986165 Drug: Placebo
  • Phase:

    Phase 2

  • Ages Eligible for Study:

    18 Years and 75 Years (Adult,Older Adult)

  • Sexes Eligible for Study:

    All

Inclusion Criteria:

Diagnosis of discoid/subacute cutaneous lupus erythematosus (DLE/SCLE) for at least 3 months prior to screening visit
Meets both clinical and histopathological diagnostic cutaneous lupus erythematosus (CLE) criteria per protocol
Currently receiving treatment for DLE/SCLE with a stable regimen of at least one of the following medications: oral corticosteroid, and/or antimalarial, and/or immunosuppressant

Exclusion Criteria:

Women who are pregnant, lactating, breastfeeding or planning pregnancy during the study period
Any of the following specific CLE subtypes in isolation: acute cutaneous lupus erythematosus (ACLE), lupus tumidus, lupus (profundus) panniculitis, chilblains
Drug-induced CLE and/or drug-induced systemic lupus erythematosus (SLE)
Antiphospholipid antibody syndrome, serious thrombotic event or unexplained pregnancy loss within 1 year before the screening visit
History of 3 or more unexplained consecutive pregnancy losses
Active severe or unstable neuropsychiatric SLE
Other autoimmune diseases or non-SLE driven inflammatory joint or skin disease or overlap syndromes as primary disease that in the opinion of the investigator will significantly impact the assessment of CLE/SLE disease manifestations and activity

Other protocol-defined inclusion/exclusion criteria apply


Participating Locations

COUNTRY
country-icon
Australia

Participating Experts

Dr. Stephen Shumack

Dermatologist

You May Also Be Interested In

Similar Trials

No Similar Trials Found
about-icon

Learn More About

Lupus

Learn More
2022 all rights reserved probity medical research inc
find a trial
filter trials

Filter By Keyword

Trial Name, Intervention and or Treatment, Trial Number, Reference Number, Study Info, Sponsors Phase, and Status.